Settlement Dominoes: The FTC’s PBM Playbook is Going Industrywide

The FTC’s insulin/pharmacy benefit managers (PBM) enforcement matter is starting to look less like a single case—and more like a regulatory reset executed through settlement. On March 3, 2026, the FTC extended the stay in its administrative proceeding against OptumRx and Caremark Rx (and affiliated entities) to allow additional time for settlement negotiations, with the parties disclosing that they are making “significant progress.”... By: Polsinelli